[3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine Binding to Metabotropic Glutamate Receptor Subtype 5 in Rodent Brain: In Vitro and in Vivo Characterization
- Jeffery J. Anderson1,
- Sara P. Rao1,
- Blake Rowe1,
- Darlene R. Giracello1,
- Greg Holtz1,
- Deborah F. Chapman1,
- Lida Tehrani2,
- Margaret J. Bradbury1,
- Nicholas D. P. Cosford2 and
- Mark A. Varney1
- Departments of 1Neuropharmacology (J.J.A., S.P.R., B.R., D.R.G., G.H., D.F.C., M.J.B., M.A.V.) and 2Medicinal Chemistry (L.T., N.D.P.C.), Merck Research Laboratories, San Diego, California
- Dr. Jeffery J. Anderson, Merck Research Laboratories, MRLSDB1, 3535 General Atomics Court, San Diego, CA 92121. E-mail: jeffery_anderson{at}merck.com
Abstract
The binding of [3H]methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (methoxymethyl-MTEP), a potent and selective antagonist for metabotropic glutamate (mGlu)5 receptors, was characterized in rat brain both in vitro and in vivo. Nonspecific binding, as defined with 10 μM 2-methyl-6-(phenylethynyl)-pyridine (MPEP), was less than 10% of total binding in rat brain membranes. The binding of [3H]methoxymethyl-MTEP was of high affinity (Kd = 20 ± 2.7 nM), saturable (Bmax = 487 ± 48 fmol/mg protein), and to a single site. The mGlu5 antagonists methoxymethyl-MTEP and MPEP displaced [3H]methoxymethyl-MTEP binding with IC50values of 30 and 15 nM, respectively. In vivo administration of [3H]methoxymethyl-MTEP (50 μCi/kg i.v.) revealed 12-fold higher binding in hippocampus (an area enriched in mGlu5 receptors) relative to cerebellum (an area with few mGlu5 receptors) in rats. Similarly, administration of [3H]methoxymethyl-MTEP to mGlu5-deficient mice demonstrated binding at background levels in forebrain, whereas wild-type littermates exhibited 17-fold higher binding in forebrain relative to cerebellum. Systemic administration of unlabeled mGlu5 antagonists methoxymethyl-MTEP and MPEP to rats reduced the binding of [3H]methoxymethyl-MTEP with ID50 values of 0.8 and 2 mg/kg i.p., respectively, 1 h post-treatment. The mGlu5 agonist 2-chloro-5-hydroxyphenylglycine (CHPG) (0.3, 1, and 3 μmol) dose-dependently increased phosphoinositide (PI) hydrolysis in the hippocampus after i.c.v. administration in rats. CHPG-evoked increases in PI hydrolysis were blocked with MPEP at a dose (10 mg/kg i.p.) that markedly reduced [3H]methoxymethyl-MTEP binding in vivo. These results indicate that [3H]methoxymethyl-MTEP is a selective radioligand for labeling mGlu5 and is useful for studying the binding of mGlu5 receptors in rat brain in vitro and in vivo.
Footnotes
-
DOI: 10.1124/jpet.102.040618
- Abbreviations:
- mGluR
- metabotropic glutamate receptor
- DHPG
- 3,5-dihydroxyphenylglycine
- MPEP
- 2-methyl-6-(phenylethynyl)-pyridine
- MTEP
- 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine
- CHPG
- 2-chloro-5-hydroxyphenylglycine
- PBS
- phosphate-buffered saline
- CHAPS
- 3-[(3-cholamidopropyl)dimethylammonio]propanesulfonate
- PI
- phosphoinositide
-
- Received June 20, 2002.
- Accepted August 9, 2002.
- The American Society for Pharmacology and Experimental Therapeutics



